Pattern recognition receptors: function, regulation and therapeutic potential [0.03%]
模式识别受体：功能、调控及治疗潜力
Ruochan Chen,Ju Zou,Jiawang Chen et al.
Ruochan Chen et al.
Pattern recognition receptors (PRRs) are sensors in the immune system, detecting pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). They serve as essential links between the innate and adaptive ...
Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy [0.03%]
CAR-T细胞治疗后的认知障碍及其他长期影响
Kathrin Gabriel,Sebastian Kobold
Kathrin Gabriel
Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair [0.03%]
伊立替康通过抑制AARS1介导的BLM乳酸化及同源重组修复缓解蒽环类药物耐药性
Xinyuan Li,Chunlin Zhang,Yuhua Mei et al.
Xinyuan Li et al.
Chemoresistance remains the major barrier to cancer treatment. Metabolic and epigenetic reprogramming are involved in this process; however, the precise roles and mechanisms are largely unknown. Here, we report that lactate-induced lactylat...
Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery [0.03%]
肺腺癌中的CD155靶向治疗：基于A5纳米体的精准治疗和增强药物递送疗法
Kyunghee Noh,Soyeon Yi,Hyeran Kim et al.
Kyunghee Noh et al.
This study presents a novel approach targeting CD155, an overexpressed protein in lung adenocarcinoma (LUAD), using nanobodies with exceptional precision and efficacy. The significant upregulation of CD155 in LUAD, associated with poor pati...
Glioblastoma at the crossroads: current understanding and future therapeutic horizons [0.03%]
胶质母细胞瘤的现状与未来治疗前景
Shilpi Singh,Devanjan Dey,Debashis Barik et al.
Shilpi Singh et al.
Glioblastoma (GBM) remains the most aggressive and lethal brain tumor in adults and poses significant challenges to patient survival. This review provides a comprehensive exploration of the molecular and genetic landscape of GBM, focusing o...
A novel peptide 66CTG stabilizes Myc proto-oncogene protein to promote triple-negative breast cancer growth [0.03%]
一种新型肽66CTG可稳定Myc原癌基因蛋白以促进三阴性乳腺癌生长
Huichun Liang,Fubing Li,Huan Fang et al.
Huichun Liang et al.
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer that lacks reliable targets for diagnosis and therapy. Non-coding RNA (ncRNA)-encoded products hold promise for addressing this unmet need. By analyzing the...
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations [0.03%]
转铁蛋白受体1核转移通过p53介导的染色质相互作用和全基因组变化促进肿瘤进展
Yaxin Hou,Guoheng Tang,Qizhi Wang et al.
Yaxin Hou et al.
Transferrin receptor 1 (TfR1), a widely expressed type II transmembrane glycoprotein located on the plasma membrane, is well known for its established role in cellular iron uptake. Nevertheless, emerging evidence implies that TfR1 exhibits ...
Acevaltrate as a novel ferroptosis inducer with dual targets of PCBP1/2 and GPX4 in colorectal cancer [0.03%]
靶向PCBP1/2和GPX4的新型铁死亡诱导剂Acevaltrate在结直肠癌中的作用
Dianping Yu,Hongmei Hu,Qing Zhang et al.
Dianping Yu et al.
Ferroptosis induced by ferrous ions (Fe2+) and lipid peroxidation accumulation is a novel form of regulated cell death that has become a hot topic in tumor therapy research. Identifying small-molecule drugs that can induce ferroptosis in tu...
Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study [0.03%]
替雷利珠单抗（抗PD-1）联合化疗作为IB3/IIA2期宫颈癌新辅助治疗的疗效和安全性：一项前瞻性、单臂、Ⅱ期临床试验（NATIC研究）
Jindong Sheng,Haitao Luo,Xiangyu Liu et al.
Jindong Sheng et al.
The clinical benefit of neoadjuvant immunochemotherapy in locally advanced cervical cancer (LACC) remains unclear. This single-arm, phase II study (Chinese Clinical Trial Registry, ChiCTR2200065392) aimed to evaluate the efficacy and safety...
CAR-T cell therapy for cancer: current challenges and future directions [0.03%]
癌症的CAR-T细胞治疗：当前挑战与未来发展方向
Inés Zugasti,Lady Espinosa-Aroca,Klaudyna Fidyt et al.
Inés Zugasti et al.
Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this ...